Lundbeck’s Vortioxetine (Lu AA21004) Will the FDA and the EMA approve another ‘killer’ drug?

So Lundbeck are seeking approval for their latest offering Vortioxetine. This is the drug which Lundbeck director ‘Torsten Madsen’ is referring to in this video. He says ”Some of the studies that we conducted did not have the outcome that we had hoped for, so we speculate that, emm, the reason is due to a too low dosing of 21004″ (Or maybe it’s because it’s another of Lundbeck’s useless offerings!)

Lundbeck’s supposed ‘antidepressant’ patent is due to run out very soon, so they’re scrambling around for a new ‘billion dollar’ pill. Will you be the next guiney pig? Citalopram and Escitalopram (same product) have caused untold suffering and numerous deaths including suicide and homicides, so will the new offering be any different? How many people will die from this drug if it does happen to be approved by the regulators?

The Clinical Trials website include 5 ‘Vortioxetine’ clinical trials conducted in India, here. Lundbeck has already been found guilty of fraud and corruption in India. Nowone would have to consider, if Lundbeck are continuously using corrupt practices in India, as with the licencing of Deanxit here, how can their findings with LU AA21004 be relied upon? Who did they have to pay to get the right results this time?

Will the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) allow another killer drug to slip through the net?

Deanxit Fraud 

Lundbeck ethics

Brussles Court find Citalopram and Escitalopram to be the same product.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s